Rongchang Biotechnology: The new indication for the treatment of locally advanced or metastatic urothelial carcinoma with HER2 expression using the combination of vedolizumab and trastuzumab has been approved for new drug market application.

Rongchang Bio announced that the company has received the "Drug Registration Certificate" issued by the China National Medical Products Administration. Vedixi Tuximab has obtained approval for a new drug application for the new indication of using in combination with Trastuzumab to treat HER2-expressing locally advanced or metastatic urothelial carcinoma. This is the fifth indication for Vedixi Tuximab to be approved in China.